BG106249A - Composition of a-beta peptide and process for producing same - Google Patents

Composition of a-beta peptide and process for producing same

Info

Publication number: BG106249A
Authority: BG; Bulgaria
Prior art keywords: composition; producing same; beta peptide; compositions; abeta peptide
Prior art date: 1999-06-01

Application number

BG106249A

Other languages

Bulgarian (bg)

English (en)

Inventor

Pamela Hirtzer

Naina Patel

Original Assignee

Neuralab, Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-01

Filing date

2001-12-20

Publication date

2002-08-30

2001-12-20 Application filed by Neuralab, Ltd filed Critical Neuralab, Ltd

2002-08-30 Publication of BG106249A publication Critical patent/BG106249A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Zoology (AREA)
Psychiatry (AREA)
Marine Sciences & Fisheries (AREA)
Hospice & Palliative Care (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

BG106249A 1999-06-01 2001-12-20 Composition of a-beta peptide and process for producing same BG106249A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13704799P	1999-06-01	1999-06-01
PCT/US2000/015302 WO2000072870A1 (en)	1999-06-01	2000-06-01	Compositions of a-beta peptide and processes for producing same

Publications (1)

Publication Number	Publication Date
BG106249A true BG106249A (en)	2002-08-30

Family

ID=22475602

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG106249A BG106249A (en)	1999-06-01	2001-12-20	Composition of a-beta peptide and process for producing same

Country Status (25)

Country	Link
EP (1)	EP1181040A1 (es)
JP (1)	JP2003519620A (es)
KR (1)	KR20020016813A (es)
CN (1)	CN1353615A (es)
AR (1)	AR024558A1 (es)
AU (1)	AU5726100A (es)
BG (1)	BG106249A (es)
BR (1)	BR0011251A (es)
CA (1)	CA2374897A1 (es)
CZ (1)	CZ20014150A3 (es)
EE (1)	EE200100649A (es)
HK (1)	HK1045938A1 (es)
HR (1)	HRP20010901A2 (es)
IL (1)	IL146575A0 (es)
IS (1)	IS6182A (es)
MX (1)	MXPA01012355A (es)
NO (1)	NO20015859L (es)
NZ (1)	NZ515744A (es)
PE (1)	PE20010212A1 (es)
PL (1)	PL352575A1 (es)
RU (1)	RU2001135800A (es)
SK (1)	SK17012001A3 (es)
TR (1)	TR200103476T2 (es)
WO (1)	WO2000072870A1 (es)
ZA (1)	ZA200109704B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US6750324B1 (en)	1997-12-02	2004-06-15	Neuralab Limited	Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
EP2082749A3 (en)	2000-07-07	2010-06-30	Bioarctic Neuroscience AB	Prevention and treatment of Alzheimer's disease
AU1225702A (en) *	2000-09-19	2002-04-02	Evotec Neurosciences Gmbh	Methods and compounds for treating brain amyloidosis
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
MY144532A (en)	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI306458B (en)	2003-05-30	2009-02-21	Elan Pharma Int Ltd	Humanized antibodies that recognize beta amyloid peptide
SE0401601D0 (sv)	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
JP2008523815A (ja)	2004-12-15	2008-07-10	エランファーマインターナショナルリミテッド	認知の改善における使用のためのヒト化アミロイドβ抗体
CN117903302A (zh)	2005-11-30	2024-04-19	Abbvie 公司	抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
ES2453941T5 (es)	2005-11-30	2017-05-31	Abbvie Inc.	Anticuerpos monoclonales contra la proteína beta amiloide y usos de los mismos
AU2007227813B2 (en)	2006-03-23	2012-09-27	Bioarctic Neuroscience Ab	Improved protofibril selective antibodies and the use thereof
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en)	2007-02-27	2008-09-04	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
PL2182983T3 (pl)	2007-07-27	2014-10-31	Janssen Alzheimer Immunotherap	Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
CN104744591B (zh)	2010-04-15	2022-09-27	Abbvie德国有限责任两合公司	β淀粉样蛋白结合蛋白
WO2012024187A1 (en)	2010-08-14	2012-02-23	Abbott Laboratories	Amyloid-beta binding proteins
GB201113570D0 (en)	2011-08-05	2011-09-21	Glaxosmithkline Biolog Sa	Vaccine
IL282823B2 (en)	2014-07-10	2024-05-01	Eisai Res And Development Management Co Ltd	A beta protofibril binding antibodies and uses thereof
PL3400019T3 (pl)	2016-01-08	2023-01-23	Ascendis Pharma Growth Disorders A/S	Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy
IL259659B (en)	2016-01-08	2022-08-01	Ascendis Pharma Growth Disorders As	Controlled-release cnp agonists with increased nep stability
CN114957438B (zh) *	2022-06-28	2024-04-02	福建亿彤生物科技有限公司	用于检测阿尔茨海默病的人Aβ1-42抗原决定簇多肽及制法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991016819A1 (en) *	1990-04-27	1991-11-14	Molecular Rx., Inc.	Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein
TWI239847B (en) *	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

2000
- 2000-05-31 PE PE2000000521A patent/PE20010212A1/es not_active Application Discontinuation
- 2000-05-31 AR ARP000102690A patent/AR024558A1/es unknown
- 2000-06-01 JP JP2001511317A patent/JP2003519620A/ja not_active Withdrawn
- 2000-06-01 CN CN00808374A patent/CN1353615A/zh active Pending
- 2000-06-01 TR TR2001/03476T patent/TR200103476T2/xx unknown
- 2000-06-01 PL PL00352575A patent/PL352575A1/xx not_active Application Discontinuation
- 2000-06-01 NZ NZ515744A patent/NZ515744A/en unknown
- 2000-06-01 KR KR1020017015474A patent/KR20020016813A/ko not_active Application Discontinuation
- 2000-06-01 CA CA002374897A patent/CA2374897A1/en not_active Abandoned
- 2000-06-01 EP EP00942668A patent/EP1181040A1/en not_active Withdrawn
- 2000-06-01 AU AU57261/00A patent/AU5726100A/en not_active Abandoned
- 2000-06-01 RU RU2001135800/14A patent/RU2001135800A/ru unknown
- 2000-06-01 MX MXPA01012355A patent/MXPA01012355A/es unknown
- 2000-06-01 BR BR0011251-8A patent/BR0011251A/pt not_active Application Discontinuation
- 2000-06-01 SK SK1701-2001A patent/SK17012001A3/sk unknown
- 2000-06-01 CZ CZ20014150A patent/CZ20014150A3/cs unknown
- 2000-06-01 EE EEP200100649A patent/EE200100649A/xx unknown
- 2000-06-01 IL IL14657500A patent/IL146575A0/xx unknown
- 2000-06-01 WO PCT/US2000/015302 patent/WO2000072870A1/en not_active Application Discontinuation
2001
- 2001-11-26 ZA ZA200109704A patent/ZA200109704B/en unknown
- 2001-11-29 IS IS6182A patent/IS6182A/is unknown
- 2001-11-30 NO NO20015859A patent/NO20015859L/no not_active Application Discontinuation
- 2001-12-04 HR HR20010901A patent/HRP20010901A2/hr not_active Application Discontinuation
- 2001-12-20 BG BG106249A patent/BG106249A/xx unknown
2002
- 2002-08-23 HK HK02106241.2A patent/HK1045938A1/zh unknown

Also Published As

Publication number	Publication date
EP1181040A1 (en)	2002-02-27
KR20020016813A (ko)	2002-03-06
BR0011251A (pt)	2002-03-05
TR200103476T2 (tr)	2002-04-22
MXPA01012355A (es)	2003-06-24
NO20015859D0 (no)	2001-11-30
PL352575A1 (en)	2003-08-25
IL146575A0 (en)	2002-07-25
AU5726100A (en)	2000-12-18
WO2000072870A1 (en)	2000-12-07
HRP20010901A2 (en)	2003-04-30
CN1353615A (zh)	2002-06-12
IS6182A (is)	2001-11-29
EE200100649A (et)	2003-02-17
AR024558A1 (es)	2002-10-16
RU2001135800A (ru)	2003-08-20
SK17012001A3 (sk)	2002-06-04
ZA200109704B (en)	2003-02-26
HK1045938A1 (zh)	2002-12-20
NZ515744A (en)	2004-04-30
CZ20014150A3 (cs)	2002-05-15
PE20010212A1 (es)	2001-02-22
CA2374897A1 (en)	2000-12-07
NO20015859L (no)	2002-02-01
JP2003519620A (ja)	2003-06-24

Publication	Publication Date	Title
BG106249A (en)	2002-08-30	Composition of a-beta peptide and process for producing same
BG66103B1 (bg)	2011-04-29	Кондензирани пиролокарбазоли
BG66083B1 (bg)	2011-03-31	Фармацевтични състави, съдържащи антитела и антитела за профилактика и лечение на амилоидогенно заболяване
WO2002002506A3 (en)	2002-08-29	Compounds to treat alzheimer's disease
WO2002002512A3 (en)	2003-08-21	Compounds to treat alzheimer's disease
ES2114471A1 (es)	1998-05-16	Nuevos compuestos de paroxetina y procedimiento para su preparacion.
AU2001252958A1 (en)	2001-10-03	Compounds and methods to treat alzheimer's disease
DE69111642D1 (de)	1995-09-07	Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten.
DE60016461D1 (de)	2005-01-05	Verfahren zur behandlung von glassubstraten und glassubstraten zur herstellung von anzeigeschirmen
IL189629A0 (en)	2008-06-05	Compositions containing human ctla-4 antibodies
IL193814A0 (en)	2009-05-04	1 -acetyl- 3,3 dimethyl- 6- amino- 2, 3 - dihydroindole and process for producing same
MXPA04005376A (es)	2004-10-04	Composiciones farmaceuticas y sus usos.
ATE430193T1 (de)	2009-05-15	Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
TW200502221A (en)	2005-01-16	Novel lactams and uses thereof
MXPA04000338A (es)	2004-07-23	Diamindioles para tratamiento de enfermedad de alzheimer.
AU1618000A (en)	2000-05-29	Use of radioligands to screen inhibitors of amyloid-beta peptide production
ATE401072T1 (de)	2008-08-15	1-arylsulfonyl-3-substituierte indol und indolinederivate verwendbar zur behandlung von erkrankungen des zentralnervensystem
MXPA03011521A (es)	2004-03-18	Aminadioles para tratamiento de enfermedad de alzheimer.
RS8504A (en)	2007-02-05	Novel cyclohexil sulphones
IL141325A0 (en)	2002-03-10	Tan-1057 derivatives
DE69805305D1 (de)	2002-06-13	Verwendung von phanquinon zur behandlung von alzheimer's krankheit
BG102707A (en)	1999-09-30	New triazolopurinpurines, method for their preparation and appplication as medicamentous forms
TW200504036A (en)	2005-02-01	Novel lactams and uses thereof
MXPA04000337A (es)	2004-07-23	Amindioles para tratamiento de enfermedad de alzheimer.
EP1446400A4 (en)	2005-06-01	Piperidin derivatives, process for their preparation and pharmaceutical composition for the treatment of Alzheimer's disease containing these derivatives